{"ok":true,"trend":{"id":443777,"platform":"news","region":"global","key":"triple agonist retatrutide pushes weight loss to new levels in type 2 diabetes","title":"Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes","url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQLUJuMzd3b29uYVQ2cW9Ga1NSZkZEWXBtdmNIQUd0VHNlS0J1cHBvUDdUaWc0Wk9pVmJuMXNLX0xVVXFvMk9tODU3d09yTnhWaDMxZ1VCdXBqSmVtWjhhZUhrTTlsTkY2RGJoaHYwVmxXc0k5YnpGclQ5OTZtM0ozaGpRSnlTMkJrUUNGVXc3Q0sxd0lpTFNma2pGTi1VZVZ3dll4dFpRNDRVNWhRVEhQaGlBdko1bzBvTVVTMWZHWnFLTHZTaGhRY3h5RE5NQy1Va0oxOG9qaUxkMDJpTnc?oc=5","first_seen":"2026-09-30T05:00:36.805213Z","last_seen":"2026-09-30T11:50:55.351445Z","last_rank":35,"peak_rank":22,"last_volume":null,"peak_volume":0,"seen_count":6,"score":0.82125,"category_hint":"medicine","section":"health","category":"medicine","summary":"Eli Lilly's triple agonist retatrutide has been reported to push weight loss to new levels among patients with type 2 diabetes, according to Inside Precision Medicine. The drug, which targets three hormone receptors, is being studied as one of the most powerful obesity and diabetes treatments in development, extending gains seen with tirzepatide and semaglutide.","why":"New results for an experimental obesity and diabetes drug are generating attention amid huge demand for GLP-1 therapies.","tone":"positive","entities":["Eli Lilly","retatrutide","type 2 diabetes"],"summarized_at":"2026-09-30T11:02:42.741573Z","meta":{"via":"scan","lang":"en","term":"medicine","source":"insideprecisionmedicine.com","published":"Tue, 29 Sep 2026 22:01:52 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Retatrutide Shows Record Weight Loss in Type 2 Diabetes Trial","section_name":"Health","category_name":"Medicine","timeline":[{"captured_at":"2026-09-30T05:00:36.805213Z","rank":22,"volume":null},{"captured_at":"2026-09-30T06:22:52.532462Z","rank":25,"volume":null},{"captured_at":"2026-09-30T07:44:52.582735Z","rank":31,"volume":null},{"captured_at":"2026-09-30T09:06:53.894595Z","rank":28,"volume":null},{"captured_at":"2026-09-30T10:28:53.107499Z","rank":31,"volume":null},{"captured_at":"2026-09-30T11:50:55.351445Z","rank":35,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQLUJuMzd3b29uYVQ2cW9Ga1NSZkZEWXBtdmNIQUd0VHNlS0J1cHBvUDdUaWc0Wk9pVmJuMXNLX0xVVXFvMk9tODU3d09yTnhWaDMxZ1VCdXBqSmVtWjhhZUhrTTlsTkY2RGJoaHYwVmxXc0k5YnpGclQ5OTZtM0ozaGpRSnlTMkJrUUNGVXc3Q0sxd0lpTFNma2pGTi1VZVZ3dll4dFpRNDRVNWhRVEhQaGlBdko1bzBvTVVTMWZHWnFLTHZTaGhRY3h5RE5NQy1Va0oxOG9qaUxkMDJpTnc?oc=5","author":"Inside Precision Medicine","title":"Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes","snippet":null,"posted_at":"2026-09-29T22:01:52Z","likes":null}],"elsewhere":[],"window":"7d"}}